The contribution of comorbidities to mortality in hospitalized patients with heart failure.

Autor: Riedel O; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstrasse 30, 28359, Bremen, Germany. riedel@leibniz-bips.de., Ohlmeier C; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstrasse 30, 28359, Bremen, Germany.; IGES Institut GmbH, Berlin, Germany., Enders D; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstrasse 30, 28359, Bremen, Germany., Elsässer A; Department of Cardiology, Klinikum Oldenburg, AöR, Oldenburg, Germany., Vizcaya D; Epidemiology, Bayer AG, Berlin, Germany., Michel A; Epidemiology, Bayer AG, Berlin, Germany., Eberhard S; AOK Niedersachsen, Hanover, Germany., Schlothauer N; Hausarztpraxis Dr. Stephan Spiekermann&Partner im Gesundheitszentrum, Delmenhorst, Germany., Berg J; AOK Bremen/Bremerhaven, Bremerhaven, Germany., Garbe E; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Achterstrasse 30, 28359, Bremen, Germany.
Jazyk: angličtina
Zdroj: Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2018 Jun; Vol. 107 (6), pp. 487-497. Date of Electronic Publication: 2018 Feb 05.
DOI: 10.1007/s00392-018-1210-x
Abstrakt: Background: Heart failure (HF) with reduced ejection fraction (HFrEF) has a worse prognosis than HF with preserved EF (HFpEF). The study aimed to evaluate whether different comorbidity profiles of HFrEF- and HFpEF-patients or HF-specific mechanisms contribute to a greater extent to this difference.
Methods: We linked data from two health insurances to data from a cardiology clinic hospital information system. Patients with a hospitalization with HF in 2005-2011, categorized as HFrEF (EF < 45%) or HFpEF (EF ≥ 45%), were propensity score (PS) matched to controls without HF on comorbidites and medication to assure similar comorbidity profiles of patients and their respective controls. The balance of the covariates in patients and controls was compared via the standardized difference (SDiff). Age-standardized 1-year mortality rates (MR) with 95% confidence intervals (CI) were calculated.
Results: 777 HFrEF-patients (1135 HFpEF-patients) were PS-matched to 3446 (4832) controls. Balance between patients and controls was largely achieved with a SDiff < 0.1 on most variables considered. The age-standardized 1-year MRs per 1000 persons in HFrEF-patients and controls were 267.8 (95% CI 175.9-359.8) and 86.1 (95% CI 70.0-102.3). MRs in HFpEF-patients and controls were 166.2 (95% CI 101.5-230.9) and 61.5 (95% CI 52.9-70.1). Thus, differences in MRs between patients and their controls were higher for HFrEF (181.7) than for HFpEF (104.7).
Conclusions: Given the similar comorbidity profiles between HF-patients and controls, the higher difference in mortality rates between HFrEF-patients and controls points more to HF-specific mechanisms for these patients, whereas for HFpEF-patients a higher contribution of comorbidity is suggested by our results.
Databáze: MEDLINE
Externí odkaz: